Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination.

Kaku CI, Champney ER, Normark J, Garcia M, Johnson CE, Ahlm C, Christ W, Sakharkar M, Ackerman ME, Klingström J, Forsell MNE, Walker LM

Science - (-) eabn2688 [2022-02-10; online 2022-02-10]

Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy. We longitudinally profiled SARS-CoV-2 spike (S)-specific serological and memory B cell (MBC) responses in individuals receiving either homologous (ChAdOx1:ChAdOx1) or heterologous (ChAdOx1:mRNA-1273) prime-boost vaccination. Heterologous mRNA booster immunization induced higher serum neutralizing antibody and MBC responses against SARS-CoV-2 variants of concern (VOCs) compared to homologous ChAdOx1 boosting. Specificity mapping of circulating B cells revealed that mRNA-1273 boost immunofocused ChAdOx1-primed responses onto epitopes expressed on prefusion-stabilized S. Monoclonal antibodies isolated from mRNA-1273 boosted participants displayed overall higher binding affinities and increased breadth of reactivity against VOCs relative to those isolated from ChAdOx1-boosted individuals. Overall, the results provide molecular insight into the enhanced quality of the B cell response induced following heterologous mRNA booster vaccination.

Category: Biochemistry

Category: Health

Category: Vaccines

Funder: KAW/SciLifeLab

Type: Journal article

PubMed 35143256

DOI 10.1126/science.abn2688

Crossref 10.1126/science.abn2688


Publications 7.1.2